Investor Dashboard

News Releases

Date Title and Summary Additional Formats
Toggle Summary NuCana to Present at the 2020 Jefferies Virtual Healthcare Conference
EDINBURGH, United Kingdom , May 27, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith , Chief Executive Officer, and Don Munoz , Chief Financial Officer, will present and host one-on-one meetings at the Jefferies Virtual Healthcare Conference .
View HTML
Toggle Summary NuCana Reports First Quarter 2020 Financial Results and Provides Business Update
Clinical Studies Re-Opened to New Patient Enrollment Following Temporary Pause Due to COVID-19 Pandemic Numerous Clinical Data Announcements Expected in 2020 Cash and Cash Equivalents Expected to Fund Operations At Least into the Fourth Quarter of 2021 EDINBURGH, United Kingdom , May 19, 2020
View HTML
Toggle Summary NuCana Announces the Re-Opening of Enrollment in Multiple Clinical Studies After Temporary Pause Due to COVID-19 Pandemic
EDINBURGH, United Kingdom , May 18, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced it has re-commenced enrollment of new patients in multiple clinical studies following the temporary pause necessitated by the COVID-19 pandemic. NuCana previously announced the re-opening of its global
View HTML
Toggle Summary NuCana to Present Two Abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2020
Non-Clinical Findings Suggest that Acelarin and NUC-3373 May Induce an Immune Response Against Cancer Cells Acelarin (NUC-1031) Releases DAMPs and Upregulates PD-L1 Expression in Lung Cancer Cells NUC-3373 Induces Endoplasmic Reticulum Stress and Release of DAMPs in Colorectal Cancer Cells
View HTML
Toggle Summary NuCana Announces Re-Opening of Global Phase III Study of Acelarin Plus Cisplatin in Patients with Biliary Tract Cancer (NuTide:121)
EDINBURGH, U.K. , May 05, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced it has re-commenced enrollment of new patients in NuTide:121, its ongoing global Phase III study of Acelarin (NUC-1031) plus cisplatin in patients with biliary tract cancer.
View HTML
Toggle Summary NuCana Provides Update on Impact of COVID-19 on Clinical Studies
EDINBURGH, United Kingdom , April 02, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) has been closely monitoring the potential impact of the COVID-19 pandemic on its operations and announced today an update on the status of its ongoing clinical studies.
View HTML
Toggle Summary NuCana Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Business Update
First Patients Dosed in Global Phase III Biliary Tract Cancer Study (NuTide:121)  with Potential for Accelerated Approval Filing Numerous Clinical Data Announcements Expected in 2020 Cash and Cash Equivalents to Fund Operations into the Second Half of 2021 EDINBURGH, United Kingdom , March 10, 2020
View HTML
Toggle Summary NuCana Reports Preliminary Data from Phase II Study of Single-Agent Acelarin (NUC-1031) in Patients with Platinum-Resistant Ovarian Cancer
Confirmed Complete Response and Two Partial Responses Achieved in Heavily Pre-treated Population Patients had Median of Five Prior Lines of Therapy EDINBURGH, United Kingdom , March 10, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced preliminary results from part one of the Phase II
View HTML
Toggle Summary NuCana Receives Positive Opinion for Orphan Drug Designation in the European Union for Acelarin (NUC-1031) for the Treatment of Patients with Biliary Tract Cancer
EDINBURGH, United Kingdom , March 04, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) has issued a positive opinion for orphan drug designation of Acelarin for the treatment of patients with
View HTML
Toggle Summary NuCana to Present at the Cowen and Company 40th Annual Health Care Conference
EDINBURGH, United Kingdom , Feb. 25, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith , Chief Executive Officer, and Don Munoz , Chief Financial Officer, will present and host one-on-one meetings at the Cowen and Company 40 th Annual Health Care Conference in
View HTML